The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting pituitary tumors, starting from the 1970s up to today, highlighting that normalization of PRL levels, restoration of eugonadism, and reduction of tumor mass can be achieved in the majority of patients by treatment with dopamine agonists.
Dopamine Agonists: From the 1970s to Today / Auriemma, R. S.; Pirchio, R.; DE ALCUBIERRE, Dario; Pivonello, R.; Colao, A.. - In: NEUROENDOCRINOLOGY. - ISSN 0028-3835. - 109:1(2019), pp. 34-41. [10.1159/000499470]
Dopamine Agonists: From the 1970s to Today
Auriemma R. S.;DE ALCUBIERRE, DARIO;Pivonello R.;Colao A.
2019
Abstract
The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting pituitary tumors, starting from the 1970s up to today, highlighting that normalization of PRL levels, restoration of eugonadism, and reduction of tumor mass can be achieved in the majority of patients by treatment with dopamine agonists.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
